The pharmaceutical community is intrigued by retatrutide, a new dual GIP and GLP-1 agonist that’s showing remarkable results in early research. This medication works by replicating natural hormones to affect appetite and increase feelings of satisfaction , ultimately leading noticeable fat loss .